Galena reports increased Q3 net loss
Operating loss for third quarter of 2012 was $5.53m compared to operating loss $3.43m for the third quarter of 2011. The company reported a net loss of $31.22m,
The US Food and Drug Administration (FDA) has granted rare paediatric disease designation to Vanda Pharmaceuticals’ VCA-894A, an investigational antisense oligonucleotide therapy for Charcot-Marie-Tooth disease, axonal, type 2S (CMT2S).
Orphan designation provides NewLink with access to multiple incentives for drug development in EU. Incentives include decreased development costs, right to use to the centralized authorization procedure, 10-year